Literature DB >> 21593750

Is there clear and convincing evidence of cardiovascular risk with rosiglitazone?

S Kaul1, G A Diamond.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593750     DOI: 10.1038/clpt.2011.65

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  3 in total

1.  Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.

Authors:  S Wheeler; K Moore; C W Forsberg; K Riley; J S Floyd; N L Smith; E J Boyko
Journal:  Diabetologia       Date:  2013-06-25       Impact factor: 10.122

Review 2.  Something old, something new and something very old: drugs for treating type 2 diabetes.

Authors:  D Kaiser; E Oetjen
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

3.  Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial.

Authors:  Claudia E Ramirez; Hui Nian; Chang Yu; Jorge L Gamboa; James M Luther; Nancy J Brown; Cyndya A Shibao
Journal:  J Clin Endocrinol Metab       Date:  2015-11-18       Impact factor: 5.958

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.